The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Yuliya Lytvyn(University Health Network), David Z.I. Cherney(University Health Network), Hiddo J.L. Heerspink(University Medical Center Groningen), Petter Bjornstad(University of Colorado Denver), Daniël H. van Raalte(Amsterdam University Medical Centers)
Cited by 171
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990